Susquehanna International Group
RCUS icon

Susquehanna International Group’s Arcus Biosciences RCUS Stock Holding History

Susquehanna International Group’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.1M Sell
143,371
-198,494
-58% -$4.29M ﹤0.01% 5211
2025
Q4 		$8.15M Sell
341,865
-47,276
-12% -$965K ﹤0.01% 3321
2025
Q3 		$5.29M Buy
389,141
+40,681
+12% +$423K ﹤0.01% 3996
2025
Q2 		$2.84M Buy
348,460
+240,021
+221% +$2.05M ﹤0.01% 5068
2025
Q1 		$851K Buy
108,439
+34,185
+46% +$396K ﹤0.01% 7660
2024
Q4 		$1.11M Buy
74,254
+932
+1% +$15.2K ﹤0.01% 6700
2024
Q3 		$1.12M Sell
73,322
-77,592
-51% -$1.22M ﹤0.01% 6523
2024
Q2 		$2.3M Sell
150,914
-164,137
-52% -$2.65M ﹤0.01% 4827
2024
Q1 		$5.95M Buy
315,051
+198,274
+170% +$3.43M ﹤0.01% 3364
2023
Q4 		$2.23M Sell
116,777
-186,865
-62% -$2.99M ﹤0.01% 5126
2023
Q3 		$5.45M Sell
303,642
-73,830
-20% -$1.48M ﹤0.01% 3368
2023
Q2 		$7.67M Buy
377,472
+115,352
+44% +$2.2M ﹤0.01% 2863
2023
Q1 		$4.78M Buy
262,120
+180,110
+220% +$3.44M ﹤0.01% 3537
2022
Q4 		$1.7M Sell
82,010
-21,991
-21% -$605K ﹤0.01% 5032
2022
Q3 		$2.72M Buy
104,001
+18,374
+21% +$486K ﹤0.01% 4278
2022
Q2 		$2.17M Sell
85,627
-49,024
-36% -$1.2M ﹤0.01% 4738
2022
Q1 		$4.25M Buy
134,651
+78,124
+138% +$2.62M ﹤0.01% 3928
2021
Q4 		$2.29M Buy
56,527
+1,440
+3% +$55.9K ﹤0.01% 5200
2021
Q3 		$1.92M Buy
55,087
+19,033
+53% +$592K ﹤0.01% 5926
2021
Q2 		$990K Buy
36,054
+12,546
+53% +$358K ﹤0.01% 7790
2021
Q1 		$660K Sell
23,508
-58,209
-71% -$2.03M ﹤0.01% 8819
2020
Q4 		$2.12M Sell
81,717
-6,310
-7% -$153K ﹤0.01% 4968
2020
Q3 		$1.51M Buy
88,027
+77,069
+703% +$1.72M ﹤0.01% 5170
2020
Q2 		$271K Buy
+10,958
New +$296K ﹤0.01% 8529
2019
Q4 		– Sell
-20,271
Closed -$184K – 10456
2019
Q3 		$184K Buy
20,271
+5,350
+36% +$43K ﹤0.01% 9175
2019
Q2 		$119K Buy
+14,921
New +$149K ﹤0.01% 9524

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Susquehanna International Group's RCUS Position: Q1 2026 in Review

Susquehanna International Group reduced its Arcus Biosciences (RCUS) stake by 58% in Q1 2026, selling an estimated $4.29M and leaving 143,371 shares worth $3.1M. The position accounts for ﹤0.01% of the portfolio, ranked #5211.

Susquehanna International Group first reported a position in RCUS in Q2 2019 and has held it in 26 quarters since. The position peaked at $8.15M in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Susquehanna International Group held 143,371 shares of Arcus Biosciences worth $3.1M as of Q1 2026.
  • Susquehanna International Group sold 198,494 Arcus Biosciences shares in Q1 2026, an estimated $4.29M.
  • Arcus Biosciences made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #5211 holding.
  • Susquehanna International Group first reported a position in Arcus Biosciences in Q2 2019 and has held it in 26 quarters since.
  • Susquehanna International Group's Arcus Biosciences position peaked at $8.15M in Q4 2025.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.